vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and LIFECORE BIOMEDICAL, INC. \DE\ (LFCR). Click either name above to swap in a different company.
LIFECORE BIOMEDICAL, INC. \DE\ is the larger business by last-quarter revenue ($31.1M vs $16.5M, roughly 1.9× FrontView REIT, Inc.). FrontView REIT, Inc. runs the higher net margin — -24.9% vs -32.1%, a 7.2% gap on every dollar of revenue.
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
FVR vs LFCR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $31.1M |
| Net Profit | $-4.1M | $-10.0M |
| Gross Margin | — | 25.0% |
| Operating Margin | — | -9.9% |
| Net Margin | -24.9% | -32.1% |
| Revenue YoY | — | -4.5% |
| Net Profit YoY | — | -52.0% |
| EPS (diluted) | $-0.19 | $-0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | — | ||
| Q3 25 | $16.8M | $31.1M | ||
| Q2 25 | $17.6M | — | ||
| Q1 25 | $16.2M | $35.2M | ||
| Q4 24 | — | $32.6M | ||
| Q3 24 | $14.5M | $24.7M | ||
| Q1 24 | — | $35.7M | ||
| Q4 23 | — | $30.1M |
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $4.0M | $-10.0M | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-833.0K | $-14.8M | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | $-2.4M | $-16.2M | ||
| Q1 24 | — | $15.6M | ||
| Q4 23 | — | $14.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | 25.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 28.0% | ||
| Q4 24 | — | 34.0% | ||
| Q3 24 | — | 21.8% | ||
| Q1 24 | — | 33.3% | ||
| Q4 23 | — | 33.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | -9.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -25.7% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | — | -46.9% | ||
| Q1 24 | — | -2.5% | ||
| Q4 23 | — | -4.9% |
| Q4 25 | -24.9% | — | ||
| Q3 25 | 23.9% | -32.1% | ||
| Q2 25 | -16.5% | — | ||
| Q1 25 | -5.1% | -42.0% | ||
| Q4 24 | — | -20.2% | ||
| Q3 24 | -16.7% | -65.7% | ||
| Q1 24 | — | 43.8% | ||
| Q4 23 | — | 47.2% |
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $0.19 | $-0.29 | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.06 | $-0.47 | ||
| Q4 24 | — | $-0.25 | ||
| Q3 24 | — | $-0.53 | ||
| Q1 24 | — | $0.42 | ||
| Q4 23 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $18.9M |
| Total DebtLower is stronger | $314.3M | $136.0M |
| Stockholders' EquityBook value | $391.2M | $-10.5M |
| Total Assets | $854.4M | $235.2M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | — | ||
| Q3 25 | $19.6M | $18.9M | ||
| Q2 25 | $8.4M | — | ||
| Q1 25 | $3.3M | $5.4M | ||
| Q4 24 | — | $9.5M | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | $136.0M | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | $124.9M | ||
| Q4 24 | — | $111.3M | ||
| Q3 24 | — | $106.3M | ||
| Q1 24 | — | $97.1M | ||
| Q4 23 | — | $92.9M |
| Q4 25 | $391.2M | — | ||
| Q3 25 | $385.2M | $-10.5M | ||
| Q2 25 | $369.9M | — | ||
| Q1 25 | $324.7M | $2.2M | ||
| Q4 24 | — | $15.4M | ||
| Q3 24 | $1.0K | $-3.9M | ||
| Q1 24 | — | $17.7M | ||
| Q4 23 | — | $1.4M |
| Q4 25 | $854.4M | — | ||
| Q3 25 | $846.8M | $235.2M | ||
| Q2 25 | $856.5M | — | ||
| Q1 25 | $860.8M | $237.7M | ||
| Q4 24 | — | $255.4M | ||
| Q3 24 | $1.0K | $246.8M | ||
| Q1 24 | — | $246.2M | ||
| Q4 23 | — | $245.8M |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | 56.05× | ||
| Q4 24 | — | 7.20× | ||
| Q3 24 | — | — | ||
| Q1 24 | — | 5.49× | ||
| Q4 23 | — | 65.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $1.8M |
| Free Cash FlowOCF − Capex | — | $25.0K |
| FCF MarginFCF / Revenue | — | 0.1% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-16.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | — | ||
| Q3 25 | $8.3M | $1.8M | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $8.1M | $1.2M | ||
| Q4 24 | — | $-6.1M | ||
| Q3 24 | — | $-613.0K | ||
| Q1 24 | — | $-1.4M | ||
| Q4 23 | — | $1.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $25.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-4.3M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | — | $-4.0M | ||
| Q1 24 | — | $-7.8M | ||
| Q4 23 | — | $-3.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -12.1% | ||
| Q4 24 | — | -26.3% | ||
| Q3 24 | — | -16.3% | ||
| Q1 24 | — | -21.8% | ||
| Q4 23 | — | -9.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | 5.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 15.5% | ||
| Q4 24 | — | 7.5% | ||
| Q3 24 | — | 13.9% | ||
| Q1 24 | — | 17.8% | ||
| Q4 23 | — | 14.1% |
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | -0.09× | ||
| Q4 23 | — | 0.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVR
Segment breakdown not available.
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
